Opportunities for Partnering

Seeking like-minded science partners

Strategic partnerships can improve the chances of delivering life-changing medicines to patients. We're constantly seeking opportunities for early-stage biologics and associated technologies, and we want to connect with partners whose areas of interest match our own.

Our areas of Interest


A targeted approach

Eliminating cancer is our goal. That focus includes pursuing innovative technologies that can do this in more effective and targeted ways, including effector-enhanced, polyspecific, and toxin-carrying antibodies. Our portfolio is robust and growing—with programs in immuno-oncology, angiogenesis inhibition, ADCs and tumor stem cells.

Collaboration interests:

  • Immune-mediated therapies
  • Tumor-associated antigens
  • Cancer stem cells
  • Oncolytic viruses
  • Engineered cellular therapies

Respiratory, Inflammation and Autoimmunity

Growing pipeline

Our Respiratory, Inflammation and Autoimmunity portfolio is rich and diverse. From pioneering innovative research to leveraging industry-leading technology, we’re delivering important and groundbreaking therapy to patients.

Collaboration interests:

  • Respiratory diseases
  • Rheumatologic autoimmune diseases
  • Neuroinflammatory autoimmune diseases
  • Inflammatory bowel diseases
  • Dermatology

Cardiovascular, Renal and Metabolism

Broadening our vision

Science has shown us that biologics have a role in the pathophysiology of Cardiovascular, Renal and Metabolic Diseases. Today, our unique capabilities and technology platforms are helping us to discover and develop novel and differentiated drugs to treat diabetic nephropathy, obesity, and cardiovascular disease.


Collaboration interests:

  • Diabetes (Type 1 and 2)
  • Obesity
  • Chronic kidney disease
  • Non-Alcoholic steatohepatitis
  • Cardiovascular disease

Infectious Disease

Prescription for the future

We know our bacteria, fungi and viruses, and we’re on a mission to explore ways of bringing biologic technology to the most challenging infectious disease needs of today and tomorrow. Our position in the industry is unique, as we investigate the intersecting roles of biologics, small molecules and vaccines.

Collaboration interests:

  • Viral infections
  • Multi-drug resistant ESKAPE pathogens
  • Other serious bacterial pathogens

Open for Opportunity

The MedImmune Partnering Team is responsible for all early stage (Phase 1 and earlier) biologics assets and associated technologies for AstraZeneca and MedImmune. For small molecule and late-stage contacts, visit the AstraZeneca Partnering page.

Contact us

Cambridge, UK:

Sir Aaron Klug Building, Granta Park Cambridge, CB21 6GH, UK

Gaithersburg, MD:

One MedImmune Way Gaithersburg, MD 20878

South San Francisco, CA:

121 Oyster Point Blvd, South San Francisco, CA 94080

Business Development Leadership

John Trainer


Gayatri Varma

Cardiovascular and Metabolic diseases

Eric Victory


Jon Kiburz

A deeper dive into our Deals